Understanding how CD4 helper cells influence cancer immunity
CD4 helper programs that regulate intratumoral immunity
This study is looking at how a type of immune cell called CD4 helper T cells can boost the body's fight against liver cancer, especially for patients getting a specific treatment, and it aims to understand how these cells work with others to make cancer therapies more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11107868 on NIH RePORTER |
What this research studies
This research investigates the role of CD4 helper T cells in enhancing the immune response against tumors, particularly in liver cancer patients receiving PD-1 targeted therapy. It aims to identify how these cells interact with other immune cells and contribute to the effectiveness of cancer immunotherapy. The study will utilize a mouse model to explore the mechanisms by which CD4 helper T cells promote the differentiation of exhausted CD8 T cells into active immune cells that can combat tumor growth. By analyzing the cellular interactions and signaling pathways involved, the research seeks to provide insights that could improve cancer treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced liver cancer who are undergoing or considering PD-1 targeted therapy.
Not a fit: Patients with early-stage cancer or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for patients with advanced cancer.
How similar studies have performed: Previous research has shown promising results in enhancing anti-tumor responses through the modulation of CD4 T cells, indicating potential for success in this approach.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Kamphorst, Alice Oliffson — Icahn School of Medicine at Mount Sinai
- Study coordinator: Kamphorst, Alice Oliffson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.